GGrantIndex
Sort

82,697 grants matching vaccine development

Development of highly potent human monoclonal for RSV immunoprophylaxis

$993,353
Ellen Monson · Mapp Biopharmaceutical, Inc. · SB1 · FY2025 · AI

Experimental Animal Models of TB: Chemotherapeutics and Imaging

$993,273
Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine

$993,161
Kenneth C Bagley · Profectus Biosciences, Inc. · R44 · FY2018 · AI

Attenuated Sporozoite Malaria Vaccine

$992,988
Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2010 · AI

Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines

$992,959
Christian Harding · Vaxnewmo, Llc · R44 · FY2021 · AI

SDMC: HIV Vaccine Trials Network

$992,886
Peter B. Gilbert · Fred Hutchinson Cancer Center · UM1 · FY2025 · AI

Acute Hepatitis C Infection in Young Injectors

$992,772
Kimberly Page · University Of California, San Francisco · R01 · FY2011 · DA

A human cytomegalovirus-based immunotherapy for HIV-1

$992,696
Eric Bruening · Tomegavax, Inc. · R44 · FY2014 · AI

Development of a Yellow Fever Vaccine for Vulnerable Population

$992,669
Ian James Amanna · Najit Technologies, Inc. · R44 · FY2012 · AI

Genital Herpes Vaccine Discovery

$992,626
Gary Fujii · Molecular Express, Inc. · R44 · FY2008 · AI

Nonhuman Primate

$992,607
Michael K Axthelm · Oregon Health & Science University · P01 · FY2014 · AI

Uncleaved prefusion-optimized trimers on nanoparticles as HIV vaccines

$992,504
Jiang Zhu · Scripps Research Institute, The · R01 · FY2019 · AI

Bio-Therapies for the Treatment of Cancer and Infectious Disease

$992,485
David Fitzgerald · Basic Sciences · Z01 · FY2007 · CA

Host Immune Responses to Antigens of Malaria Parasites

$992,457
Carole Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI

Malaria Pathogenesis and Human Immunity

$992,443
Rick Fairhurst · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI

Preclinical development of a potent D-peptide RSV inhibitor

$992,263
Brett D Welch · Navigen, Inc. · R44 · FY2016 · AI

Development of Novel Immunogens for Vaccines to HIV-1

$992,252
Robert Gerald Whalen · Altravax, Inc. · P01 · FY2009 · AI

Institute of Human Virology Clinical Trials Unit

$992,201
William Albert Blattner · University Of Maryland Baltimore · U01 · FY2008 · AI

A Solid-Phase, Long-Acting CCR5 Monoclonal Antibody for HIV Transmission

$992,151
Jonah B. Sacha · Oregon Health & Science University · R01 · FY2024 · AI

B-cell repertoire analysis in influenza vaccination and infection

$992,119
Hua-Xin Liao · Boston Children'S Hospital · P01 · FY2015 · AI

Recombinant Subunit West Nile Virus Vaccine Development

$992,079
Paul M Kaplan · L2 Diagnostics, Llc · U01 · FY2006 · AI

Northwestern University O'Brien Kidney National Resource Center

$992,052
Susan E Quaggin · Northwestern University At Chicago · U54 · FY2023 · DK

Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs

$991,947
Michelle M. Butler · Microbiotix, Inc · R44 · FY2020 · AI

PEDIATRIC AIDS CLINICAL TRIAL UNIT

$991,911
Univ Of Massachusetts Med Sch Worcester · U01 · FY2004 · AI

Design of Antigenically-Specific Probes for Sera Analysis and MAb Isolation

$991,870
Peter D Kwong · National Institute Of Allergy And Infectious Diseases · ZIC · FY2017 · AI